The estimated Net Worth of Seth Loring Harrison is at least $17.8 Milione dollars as of 30 November 2022. Seth Harrison owns over 23,131 units of Stoke Therapeutics stock worth over $2,182,449 and over the last 5 years he sold STOK stock worth over $15,056,711. In addition, he makes $525,048 as Independent Chairman of the Board at Stoke Therapeutics.
Sign up
Seth Harrison STOK stock SEC Form 4 insiders trading
Seth has made over 7 trades of the Stoke Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 23,131 units of STOK stock worth $1,085,769 on 30 November 2022.
The largest trade he's ever made was buying 1,388,889 units of Stoke Therapeutics stock on 21 June 2019 worth over $25,000,002. On average, Seth trades about 180,611 units every 66 days since 2019. As of 30 November 2022 he still owns at least 148,063 units of Stoke Therapeutics stock.
You can see the complete history of Seth Harrison stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Seth Harrison biography
Dr. Seth L. Harrison M.D. serves as Independent Chairman of the Board of the Company. Dr. Harrison serves as Managing Partner at Apple Tree Partners, a venture capital firm, which he founded in 1999. Prior to founding Apple Tree Partners, Dr. Harrison served as a General Partner at Oak Investment Partners, a venture capital and private equity firm, and as a Venture Partner at Sevin Rosen Funds, a technology-focused venture capital firm. Dr. Harrison currently serves as a member of the board of directors of Akero Therapeutics, Inc., a public biopharmaceutical company. Dr. Harrison also serves as the chairman of the boards of directors of Braeburn, Inc., a pharmaceutical company, Elstar Therapeutics, Inc., an immunotherapy company, Gala Therapeutics, Inc., a medical device company, and Limelight Bio, Inc., a gene therapy company, as well as several other private companies. Dr. Harrison holds an A.B. from Princeton University and an M.D. and M.B.A. from Columbia University. Harrison is qualified to serve on our Board of Directors because of his experience in the life sciences industry, his experience as a venture capitalist, as well as his service on the boards of directors of numerous biopharmaceutical companies.
What is the salary of Seth Harrison?
As the Independent Chairman of the Board of Stoke Therapeutics, the total compensation of Seth Harrison at Stoke Therapeutics is $525,048. There are 8 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.
What's Seth Harrison's mailing address?
Seth's mailing address filed with the SEC is 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Stoke Therapeutics
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... e Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
What does Stoke Therapeutics's logo look like?
Complete history of Seth Harrison stock trades at Akero Therapeutics Inc e Stoke Therapeutics
Stoke Therapeutics executives and stock owners
Stoke Therapeutics executives and other stock owners filed with the SEC include:
-
Stephen Tulipano,
Chief Financial Officer -
Dr. Edward M. Kaye,
CEO & Director -
Dr. Edward M. Kaye M.D., Ph.D.,
CEO & Director -
Huw Nash,
Chief Operating Officer, Chief Business Officer -
Barry Ticho,
Chief Medical Officer -
Edward Kaye,
Chief Executive Officer, Director -
Dr. Barry S. Ticho FACC, M.D., Ph.D.,
Chief Medical Officer -
Stephen J. Tulipano CPA, CPA, MBA,
Chief Financial Officer -
Seth Harrison,
Independent Chairman of the Board -
Jennifer Burstein,
Independent Director -
Adrian Krainer,
Independent Director -
Arthur Tzianabos,
Independent Director -
Arthur Levin,
Independent Director -
Dr. Adrian R. Krainer Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Garry Menzel,
Independent Director -
Julie Smith,
Independent Director -
Gene Liau,
Executive Vice President, Head of Research and Preclinical Development -
Dawn Kalmar,
Chief Communications Officer -
Jonathan Allan J.D.,
Deputy Gen. Counsel -
Dr. Gene Liau,
Chief Scientific Officer -
Dr. Huw M. Nash Ph.D.,
COO & Chief Bus. Officer -
Nancy M. Wyant,
VP & Head of Clinical Operations -
Shamim Ruff,
Chief Regulatory Officer -
Joan Wood,
Head of HR -
Isabel Aznarez Ph.D.,
Co-Founder, VP & Head of Biology -
Group, Llc Green Jeremy Red...,
-
Samuel W. Hall,
Director -
Life Science Ventures, L.P....,
-
Investments, Lpwong Roderic...,
-
Robin A. Walker,
Chief Legal Officer, CCO & Sec -
Jonathan Allan,
GENERAL COUNSEL & CORP SEC -
Trust Blue Horizon Enterpri...,
-
Thomas Leggett,
Chief Financial Officer -
Ian F Smith,